ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,390,113 | -11.6% | 309,142 | +0.2% | 0.02% | -4.8% |
| Q2 2023 | $9,485,810 | -13.0% | 308,582 | +2.0% | 0.02% | -16.0% |
| Q1 2023 | $10,899,435 | -8.4% | 302,510 | +0.4% | 0.02% | -13.8% |
| Q4 2022 | $11,903,819 | +2.0% | 301,210 | +3.7% | 0.03% | -3.3% |
| Q3 2022 | $11,673,000 | -4.4% | 290,530 | 0.0% | 0.03% | 0.0% |
| Q2 2022 | $12,214,000 | +10.3% | 290,530 | +2.2% | 0.03% | +42.9% |
| Q1 2022 | $11,074,000 | -0.6% | 284,235 | +1.7% | 0.02% | +5.0% |
| Q4 2021 | $11,137,000 | +25.5% | 279,463 | +13.8% | 0.02% | +17.6% |
| Q3 2021 | $8,873,000 | -11.1% | 245,520 | +0.8% | 0.02% | -10.5% |
| Q2 2021 | $9,983,000 | +8.7% | 243,550 | +15.7% | 0.02% | +5.6% |
| Q1 2021 | $9,185,000 | +634.2% | 210,575 | +742.3% | 0.02% | +500.0% |
| Q4 2020 | $1,251,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |